Book chapter
Hepatic and splenic involvement in sarcoidosis
Sarcoidosis, pp.223-233
ERS monograph, v. 96, European Respiratory Society
2022
DOI: 10.1183/2312508x.10032820
Abstract
Hepatic and splenic sarcoidosis are detected clinically in about 10% of sarcoidosis patients but are asymptomatic in up to 79% of cases. Splenic involvement is usually asymptomatic, and hepatic involvement can vary from asymptomatic to showing nonspecific symptoms to presenting with signs and symptoms of cirrhosis and portal hypertension. Diagnostic criteria mainly rely on compatible clinical variables in the setting of established sarcoidosis, and occasionally on pathological findings. The differential diagnosis for both hepatic and splenic involvement is wide, and careful assessment is needed to avoid misdiagnosis, as sarcoidosis is a diagnosis of exclusion. Various imaging modalities reveal organ enlargement and nodularity, but the findings are not pathognomonic for sarcoidosis. Treatment is indicated in symptomatic cases and when there is evidence of significant organ dysfunction. Ursodeoxycholic acid is a therapeutic option in predominantly hepatic sarcoidosis, and splenic and hepatic involvement tend to respond to standard anti-sarcoidosis regimens. Careful monitoring for potential complications is imperative. Liver transplantation has been successful in cases of end-stage liver disease due to sarcoidosis.
Details
- Title: Subtitle
- Hepatic and splenic involvement in sarcoidosis
- Creators
- Florence JenyNabeel Hamzeh
- Resource Type
- Book chapter
- Publication Details
- Sarcoidosis, pp.223-233
- Publisher
- European Respiratory Society
- Series
- ERS monograph; v. 96
- DOI
- 10.1183/2312508x.10032820
- Language
- English
- Date published
- 2022
- Academic Unit
- Internal Medicine; Pulmonary, Critical Care, and Occupational Medicine
- Record Identifier
- 9984528089702771
Metrics
1 Record Views